Merck has announced the cancellation of its plans for a $1.3 billion research laboratory in London, citing dissatisfactory progress in UK life sciences investment and policies. This move accompanies a broader cessation of Merck’s discovery research operations in the United Kingdom, reflecting the company’s frustration with the current pharmaceutical pricing and reimbursement environment. The exit raises concerns about the UK's competitiveness as a hub for pharmaceutical R&D and may impact the local biotech ecosystem. The decision comes shortly after Merck laid off 125 employees in the UK and amidst warnings from the Association of the British Pharmaceutical Industry about the country falling behind in life sciences investment.